Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI PharmaceuticalsCASIF +1.40%29 Days Sales Outstanding is 42.33 as of Dec. 2025, which is 63% below its 10-year median of 114.24. GuruFocus rates CASIF with a GF Score™ of 29/100 and a GF Value™ of $1.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 838 Biotechnology companies, CASI Pharmaceuticals ranks worse than 77.09% on this metric.
CASI Pharmaceuticals (OTCPK:CASIF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CASI Pharmaceuticals Days Sales Outstanding Related Terms
CASI Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASIF vs DCOY, PKTX, BIXT: Days Sales Outstanding Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Days Sales Outstanding falls into.
CASI Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (CASIF) has a Days Sales Outstanding of 42.33 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CASI Pharmaceuticals and its competitors. This is 63% below median its historical median of 114.24. Over the past decade, CASI Pharmaceuticals' Days Sales Outstanding has ranged from 71.57 to 171.27. According to the industry distribution chart, CASI Pharmaceuticals ranks #646 out of 838 companies in the Biotechnology industry, placing it in the top 77.1%.
Is CASI Pharmaceuticals' Days Sales Outstanding too high?
CASI Pharmaceuticals' current Days Sales Outstanding of 42.33 is 63% below median its 10-year median of 114.24. Over the past 10 years, this metric has ranged from a low of 71.57 to a high of 171.27. The Biotechnology industry median Days Sales Outstanding is 69.00. CASI Pharmaceuticals' value of 42.33 is 38.7% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #646 out of 838 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Days Sales Outstanding compare to DCOY and PKTX?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #646 out of 838 companies for Days Sales Outstanding. This places CASI Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 69.00. CASI Pharmaceuticals' value of 42.33 is 38.7% below this benchmark. Historically, CASI Pharmaceuticals' own Days Sales Outstanding has ranged from 71.57 to 171.27 over the past decade. While the company's 10-year median is 114.24 vs. the industry median of 69.00, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.00, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current Days Sales Outstanding of 42.33 is 38.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Days Sales Outstanding is 42.33, which is 63% below median its own 10-year median of 114.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.10, compared to a current price of $0.15 — trading 86.5% below its estimated fair value. The current Days Sales Outstanding is 42.33, which is 63% below median its 10-year median of 114.24 and 38.7% below the Biotechnology industry median of 69.00. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Days Sales Outstanding is 42.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.15 is trading 86.5% below its estimated GF Value™ of $1.10.
GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CASIF:
Days Sales Outstanding: 42.33 (63% below median its 10-year median of 114.24)
GF Value™: $1.10 vs. price of $0.15 (86.5% below fair value)
Industry Position: 38.7% below the Biotechnology median (#646 of 838)
No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for CASIF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASIF has been successfully added to your 
